Researchers from the Institute of Pharmacy in Jena studied the anti-inflammatory effects of cannabinoids, particularly focusing on CBD (cannabidiol). They found that CBD activates an enzyme leading to inflammation resolution and believe these findings could result in new treatments for inflammatory diseases.
An international research team has clarified the mode of action of cannabinoids in inflammation.
The German federal government recently made the contentious choice to decriminalize the ownership and purchase of minor quantities of cannabis.
Should the German legislature approve the draft bill, the “Cannabis Act” is set to be implemented the following year. Many believe this action is long-awaited, while others persistently caution about the health dangers associated with cannabis consumption.
The Jena researchers and their colleagues are now taking a different look at cannabis – the traditional medicinal plant – with a study published in the journal Cell Chemical Biology.
The team from the Institute of Pharmacy investigated how certain ingredients from the cannabis plant counteract inflammation. It was already known from previous studies that cannabis is not only an analgesic and an antispasmodic but also has an anti-inflammatory effect.
“However, the reason for the anti-inflammatory effect was largely unclear until now,” says Dr. Paul Mike Jordan, who led the study together with Prof. Oliver Werz.
Dr. Paul Mike Jordan (l.) investigates the actions of cannabinoids in humans with Lukas K. Peltner (r.). Credit: Anna König
The researchers studied how different cannabinoidsCannabinoids are chemical compounds found in the cannabis plant that interact with the body's endocannabinoid system, which regulates various physiological processes. The two most well-known cannabinoids are THC and CBD, which have different effects on the body and potential medical benefits.” data-gt-translate-attributes=”[{“attribute”:”data-cmtooltip”, “format”:”html”}]”>cannabinoids, including the psychoactive THC (tetrahydrocannabinol) and CBD (cannabidiolCannabidiol, commonly called CBD, is a phytocannabinoid discovered in 1940. It is one of the active ingredients of cannabis (marijuana), but unlike THC, it is not considered psychoactive. It is being studied for the possible treatment of anxiety, movement disorders, and pain. In 2018, the FDA approved the cannabidiol drug Epidiolex for treatment of two epilepsy disorders.” data-gt-translate-attributes=”[{“attribute”:”data-cmtooltip”, “format”:”html”}]”>cannabidiol), which are already found in freely available products today, act on human immune cells. “We found that all eight cannabinoids we studied had anti-inflammatory effects,” says Lukas Peltner, doctoral student and first author of the study. “All the compounds we studied were found to inhibit the formation of pro-inflammatory messenger substances in cells while enhancing the formation of inflammation-resolving substances.”
CBD induces a switch in immune cells
CBD in particular proved to be highly effective and the team investigated it in more detail with regard to its mode of action. The researchers were able to determine that CBD activates the 15-lipoxygenase-1 enzyme, which triggers the production of inflammation-resolving messenger substances that subsequently cause the inflammation to subside.
“CBD thus induces a switch in the affected cells, so to speak, which steers the inflammatory process from the promoting to the inhibiting side,” explains Dr. Jordan. The researchers were also able to confirm these results, which were obtained in cell cultures, in animal experiments on mice.
In the long term, the insights gained could lead to new therapeutic strategies for treating inflammatory diseases, the researchers conclude. The focus should be on CBD, which was the most effective cannabinoid in the study. Previously approved preparations with cannabinoids contain CBD, “but also the psychoactive THC, which can be associated with a variety of side effects,” notes Dr. Jordan. Therapeutics containing only CBD would reduce this problem.
Reference: “Cannabidiol acts as molecular switch in innate immune cells to promote the biosynthesis of inflammation-resolving lipid mediators” by Lukas K. Peltner, Lars Gluthmann, Friedemann Börner, Simona Pace, Robert K. Hoffstetter, Christian Kretzer, Rosella Bilancia, Federica Pollastro, Andreas Koeberle, Giovanni Appendino, Antonietta Rossi, Marcia E. Newcomer, Nathaniel C. Gilbert, Oliver Werz, and Paul M. Jordan, 29 August 2023, Cell Chemical Biology.
DOI: 10.1016/j.chembiol.2023.08.001
The research work has been carried out within the Collaborative Research Centres “PolyTarget” and “ChemBioSys” of the University of Jena, Germany and has been funded by the German Research Foundation.
Source: SciTechDaily
